✦ LIBER ✦

Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A

✍ Scribed by W. E. Hathaway; M. J. Christian; S. L. Clarke; U. Hasiba

Publisher: John Wiley and Sons
Year: 1984
Tongue: English
Weight: 189 KB
Volume: 17
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.2830170111

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lack of response to commercial factor VI

Lack of response to commercial factor VIII concentrate in hemophilia a

✍ George M. Rodgers; Marilyn H. Ford 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

In vitro factor VIII recovery during the

In vitro factor VIII recovery during the delivery of ultra-pure factor VIII concentrate by continuous infusion

✍ DiMichele, Donna M.; Lasak, Martin E.; Miller, Connie H. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 397 KB 👁 2 views

Factor Vlll (FVIII) replacement by continuous infusion has been advocated as a costeffective method for maintaining stable plasma levels of FVlll in the hemophilia A patient during surgery or lifethreatening hemorrhage. Continuous delivery of monoclonal or recombinant FVlll concentrates to our pedia

Stability and sterility of a recombinant

Stability and sterility of a recombinant factor viii concentrate prepared for continuous infusion administration

✍ Belgaumi, Asim F.; Patrick, Christian C.; Deitcher, Steven R. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB 👁 1 views

## Minipumps may facilitate cost-effective and convenient continuous infusion (CI) therapy for severe hemophilia A. This study evaluated the in vitro sterility, ability to support bacterial growth, and specific activity stability of a recombinant factor VIII (FVIII; Bio-clate™, Centeon) delivered

Incidence of inhibitors in patients with

Incidence of inhibitors in patients with severe and moderate hemophilia a treated with factor VIII concentrates

✍ Dr. Iise Schwarzinger; Ingrid Pabinger; Christian Korninger; Ferdinand Haschke; 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB 👁 2 views

Successful treatment of high titer inhib

Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy

✍ Daniel Robbins; Roshni Kulkarni; Renuka Gera; Ajovi B. Scott-Emuakpor; Kathy Bos 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

Mutations of the factor VIII gene in Tha

Mutations of the factor VIII gene in Thai hemophilia A patients

✍ V. Akkarapatumwong; S. Oranwiroon; P. Pung-amritt; A. Treesucon; P. Thanootaraku 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 2 views

Hemophilia A is a common X-linked bleeding disorder caused by mutations in the coagulation factor VIII gene. The entire coding and essential sequences of the factor VIII gene were generated by a combination of genomic DNA amplification and long reverse transcription-polymerase chain reaction (long R